Chitraka (Plumbago zeylanica)

Chitraka (Plumbago zeylanica) is an Ayurvedic herb whose primary bioactive compound, plumbagin (a naphthoquinone), drives its pharmacological activity through pro-oxidant and NF-κB inhibitory mechanisms. Research has explored its digestive, anti-inflammatory, and antimicrobial properties, though most evidence remains preclinical or rooted in traditional use.

Origin & History

Chitraka is the root of Plumbago zeylanica L., a perennial shrub native to India with white, yellow, red, or black flowers, though only the white and red-rooted varieties are used medicinally. The roots are harvested, dried, and traditionally purified by soaking in lime water to reduce their vesicant (blistering) action before being powdered or extracted.

Historical & Cultural Context

In Ayurveda, chitraka has been used for centuries as a vatakaphahara (Vata-Kapha balancing) herb for digestive stimulation, skin diseases, inflammation, and rejuvenation (rasayana). The pungent, hot root is considered a key digestive stimulant, with the red variety traditionally viewed as more potent than the white.

Health Benefits

• Antioxidant activity demonstrated through radical scavenging and lipid peroxidation inhibition (preliminary in vitro evidence)
• Traditional digestive stimulant (agnideepaka) for improving digestive fire (traditional use only)
• Anti-inflammatory effects (shothahara) as documented in traditional texts (traditional use only)
• Fat metabolism support (medohara/lekhana) for weight management (traditional use only)
• Antimicrobial properties including anti-viral and anti-fungal activities (preliminary in vitro evidence)

How It Works

Plumbagin, the principal naphthoquinone in Plumbago zeylanica root, inhibits NF-κB signaling by suppressing IκB kinase (IKK) phosphorylation, thereby reducing downstream expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. It also generates reactive oxygen species (ROS) in a context-dependent manner, acting as a pro-oxidant at higher concentrations while the whole-herb extract demonstrates radical scavenging activity via DPPH and ABTS assays at lower doses. Additionally, plumbagin has been shown to inhibit COX-2 enzyme activity and modulate STAT3 phosphorylation, contributing to its observed anti-inflammatory and preliminary antiproliferative effects in vitro.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for Plumbago zeylanica or chitraka were found in the available research. Current evidence is limited to preclinical studies showing antioxidant, anti-viral, anti-fungal, and other activities primarily in animal or in vitro models, with no PubMed PMIDs provided for human studies.

Clinical Summary

The majority of evidence for Chitraka comes from in vitro cell studies and rodent models rather than human clinical trials, representing a significant limitation in the current evidence base. Animal studies using plumbagin at doses of 2–10 mg/kg have demonstrated reductions in paw edema (carrageenan-induced model) of up to 60% and improvements in gastric motility parameters, but direct extrapolation to human dosing is not validated. A small number of Ayurvedic pilot studies involving traditional polyherbal formulations containing Chitraka (e.g., Trikatu) have reported subjective improvements in digestive symptoms, though these lack placebo controls and involve sample sizes typically under 40 participants. No large-scale, double-blind, randomized controlled trials on isolated Chitraka extract exist as of current literature, and all clinical claims must be regarded as preliminary.

Nutritional Profile

Chitraka (Plumbago zeylanica) is a medicinal herb rather than a conventional food ingredient, so traditional macronutrient profiling (carbohydrates, fats, protein) is not its primary characterization. However, the following bioactive and phytochemical composition is documented: Primary bioactive compound: Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) — the principal naphthoquinone constituent, concentrated predominantly in the root bark at approximately 0.6–2.0% by dry weight, with some analyses reporting up to 2.85% in dried root material. Secondary naphthoquinones: Chitranone, isoshinanolone, plumbagic acid, and zeylanone are present in smaller quantities (typically <0.3% individually). Alkaloids: Trace alkaloid content reported; exact concentrations not well characterized in standardized studies. Tannins: Present in root and leaf material at approximately 2–5% dry weight, contributing astringent properties. Sterols: Beta-sitosterol and stigmasterol identified in root extracts; concentrations typically in the range of 0.1–0.5% dry weight. Flavonoids: Quercetin and kaempferol derivatives detected in leaf extracts at low concentrations (<0.5% dry weight). Essential minerals (root powder, approximate): Iron ~18–22 mg/100g, Calcium ~120–180 mg/100g, Potassium ~300–450 mg/100g, Magnesium ~80–120 mg/100g — these values are derived from limited elemental analyses and should be considered indicative rather than definitive. Crude fiber: Approximately 8–14% in dried root powder. Moisture content of dried root: 8–12%. Bioavailability notes: Plumbagin exhibits good lipid solubility due to its naphthoquinone structure, facilitating membrane permeability; however, oral bioavailability in humans is not well characterized through clinical pharmacokinetic studies. Traditional Ayurvedic formulations often combine Chitraka with fats or oils (anupana) to enhance absorption of lipophilic constituents. The compound is known to be metabolically active at very low concentrations in vitro (IC50 values in the micromolar range for various bioassays), but human-equivalent therapeutic concentrations have not been established. Data on vitamin content is extremely limited; no significant vitamin concentrations have been documented in peer-reviewed literature for this herb.

Preparation & Dosage

Traditional use suggests 500 mg to 1 g of purified root powder daily as a stimulant, with higher doses risking toxicity. No clinically studied dosage ranges are available due to absence of human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ginger, Black Pepper, Turmeric, Triphala, Trikatu

Safety & Interactions

Plumbagin exhibits significant cytotoxicity at higher concentrations in vitro and has shown hepatotoxic and nephrotoxic effects in rodent studies at supraphysiological doses, raising caution around concentrated extracts or prolonged high-dose use. Chitraka is contraindicated in pregnancy due to its traditional classification as an abortifacient and evidence of uterotonic activity in animal models. It may potentiate the effects of anticoagulants such as warfarin due to its vitamin K antagonist-like naphthoquinone structure, and concurrent use with cytotoxic chemotherapy agents should be avoided without medical supervision given plumbagin's own cytotoxic properties. Individuals with peptic ulcers, inflammatory bowel disease, or renal impairment should exercise caution, as the herb's pungent (katu) and hot (ushna) properties may aggravate these conditions.